Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care

Project description

Reawakening the immune system to fight cancer

Tumours often deploy a variety of immune evasion strategies to escape detection and destruction by the body’s immune system. These include expression of immune checkpoint molecules to inhibit T cell activity, the expression of immunosuppressive cytokines, as well as the recruitment of regulatory T cells to dampen immune responses. Therefore, reawakening the immune system is a promising cancer treatment strategy. The EIC-funded NTX1088 project brings to the clinic an innovative antibody targeting the human poliovirus receptor (PVR) which is a key regulator of immune activation and is overexpressed in various cancer cells. The anti-PVR antibody works to restore immune cell function by activating T cells and natural killer cells against cancer.

Objective

Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients. To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patients immune system to fight cancer through a triple mechanism of action never demonstrated before. A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo. Following IND approval and strong backing from key opinion leaders, Phase I clinical trial has commenced, aimed to enrol patients with solid tumours. The project will accelerate the clinical development of NTX1088 towards a novel therapy on the 80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Coordinator

NECTIN THERAPEUTICS LTD
Net EU contribution
€ 2 499 998,90
Address
HI-TECH CAMPUS GIVAT RAM
91390 JERUSALEM
Israel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 571 427,00